Functional analysis of Fas signaling in vivo using synthetic inducers of dimerization

Current Biology

Volumn 6, Issue 7, 1996, Pages 839-847

  Spencer, David M ^a,c   Belshaw, Peter J ^b   Chen, Lei ^a   Ho, Steffan N ^a   Randazzo, Filippo ^a,d   Crabtree, Gerald R ^a   Schreiber, Stuart L ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD UNIVERSITY   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA; MUS MUSCULUS;

EID: 0030199152     PISSN: 09609822     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9822(02)00607-3     Document Type: Article

References (40)

1. Trauth BC, Klas C, Peters AM, Matzku S, Moller P, Falk W, et al.: Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989, 245:301-305.
2. Yonehara S, Ishii A, Yonehara M: A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 1989, 169:1747-1756.
3. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, et al.: The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991, 66:233-243.
4. Kerr JF, Wyllie AH, Currie AR: Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972, 26:239-257.
5. Smith CA, Farrah T, Goodwin RG: The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 1994, 76:959-962.
6. Cleveland JL, Ihle JN: Contenders in FasL/TNF death signaling. Cell 1995, 81:479-482.
7. Itoh N, Nagata S: A novel protein domain required for apoptosis. Mutational analysis of human Fas antigen. J Biol Chem 1993, 268:10932-10937.
8. Tartaglia LA, Ayres TM, Wong GH, Goeddel DV: A novel domain within the 55 kd TNF receptor signals cell death. Cell 1993, 74:845-853.
9. Cohen PL, Eisenberg RA: Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Ann Rev Immunol 1991, 9:243-269.
10. Rieux-Laucat F, Le Deist F, Hivroz C, Roberts IA, Debatin KM, Fischer A, de Villartay JP: Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 1995, 268:1347-1349.
11. cg, that complements the gld gene in induction of lymphadenopathy in the mouse. J Exp Med 1990, 171:519-531.
12. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S: Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992, 356:314-317.
13. Adachi M, Suematsu S, Kondo T, Ogasawara J, Tanaka T, Yoshida N, Nagata S: Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver. Nat Genet 1995, 11:294-300.
14. + T lymphocytes from MRL/lpr mice are resistant to receptor-mediated tolerance and apoptosis. J Immunol 1993, 151:7233-7239.
15. Owen-Schaub LB, Yonehara S, Crump WL, Grimm EA: DNA fragmentation and cell death is selectively triggered in activated human lymphocytes by Fas antigen engagement. Cell Immunol 1992, 140:197-205.
16. Klas C, Debatin KM, Jonker RR, Krammer PH: Activation interferes with the APO-1 pathway in mature human T cells, Int Immunol 1993, 5:625-630.
17. Strasser A: Death of a T cell. Nature 1995, 373:385-386.
18. + thymocytes and activated mature lymphocytes in normal mice but not in the lupus-prone strain, MRL lpr/lpr. Proc Natl Acad Sci USA 1993, 90:10340-10344.
19. + thymocytes by the anti-Fas antibody. J Exp Med 1995, 181:485-491.
20. Suda T, Takahashi T, Golstein P, Nagata S: Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993, 75:1169-1178.
21. Steinberg AD, Roths JB, Murphy ED, Steinberg RT, Raveche ES: Effects of thymectomy or androgen administration upon the autoimmune disease of MRL/Mp-lpr/lpr mice. J Immunol 1980, 125:871-873.
22. + T cells in MRL-lpr/ lpr mice. Clues from a T cell receptor beta transgenic mouse. J Immunol 1993, 150:3651-3667.
23. Spencer DM, Wandless TJ, Schreiber SL, Crabtree GR: Controlling signal transduction with synthetic ligands. Science 1993, 262:1019-1024.
24. Tanaka M, Suda T, Takahashi T, Nagata S: Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO J 1995, 14:1129-1135.
25. Dhein J, Daniel PT, Trauth BC, Oehm A, Moller P, Krammer PH: Induction of apoptosis by monoclonal antibody anti-APO-1 class switch variants is dependent on cross-linking of APO-1 cell surface antigens. J Immunol 1992, 149:3166-3173.
26. Alderson MR, Tough TW, Braddy S, Davis-Smith T, Roux E, Schooley K, Miller RE, Lynch DH: Regulation of apoptosis and T cell activation by Fas-specific mAb. Int Immunol 1994, 6:1799-1806.
27. src myristylation and membrane association and for cell transformation. Mol Cell Biol 1994, 4:1834-1842.
28. Pruschy MN, Spencer DM, Kapoor TM, Miyake H, Crabtree GR, Schreiber SL: Mechanistic studies of a signaling pathway activated by the organic ligand FK1012. Chem & Biol 1994, 1:163-172.
29. Allen JM, Forbush KA, Perlmutter RM: Functional dissection of the lck proximal promoter. Mol Cell Biol 1992, 12:2758-2768.
30. Smith RA, Baglioni C: The active form of tumor necrosis factor is a trimer. J Biol Chem 1987, 262:6951-6954.
31. Jones EY, Stuart DI, Walker NP: Structure of tumour necrosis factor. Nature 1989, 338:225-228.
32. Banner DW, D'Arcy A, Janes W, Gentz R, Schoenfeld HJ, Broger C, et al.: Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. Cell 1993, 73:431-445.
33. Boldin MP, Varfolomeev EE, Pancer Z, Mett IL, Camonis JH, Wallach D: A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J Biol Chem 1995, 270:7795-7798.
34. Boldin MP, Mett IL, Varfolomeev EE, Chumakov I, Shemer-Avni Y, Camonis JH, Wallach D: Self-association of the 'death domains' of the p55 tumor necrosis factor (TNF) receptor and Fas/APO1 prompts signaling for TNF and Fas/APO1 effects. J Biol Chem 1995, 270:387-391.
35. Song HY, Dunbar JD, Donner DB: Aggregation of the intracellular domain of the type 1 tumor necrosis factor receptor defined by the two-hybrid system. J Biol Chem 1994, 269:22492-22495.
36. Surh CD, Sprent J: T-cell apoptosis detected in situ during positive and negative selection in the thymus. Nature 1994, 372:100-103.
37. Amakawa R, Hakem A, Kundig TM, Matsuyama T, Simard JJ, Timms E, et al.: Impaired negative selection of T cells in Hodgkin's disease antigen CD30-deficient mice. Cell 1996, 84:551-562.
38. Kaye J, Porcelli S, Tite J, Jones B, Janeway CAJ: Both a monoclonal antibody and antisera specific for determinants unique to individual cloned helper T cell lines can substitute for antigen and antigen-presenting cells in the activation of T cells. J Exp Med 1983, 158:836-856.
39. Northrop JP, Ullman KS, Crabtree GR: Characterization of the nuclear and cytoplasmic components of the lymphoid-specific nuclear factor of activated T cells (NF-AT) complex. J Biol Chem 1993, 268:2917-2923.
40. Crooks ME, Littman DR, Carter RH, Fearon DT, Weiss A, Stein PH: CD28-mediated costimulation in the absence of phosphatidylinositol 3-kinase association and activation. Mol Cell Biol 1995, 15:6820-6828.